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ABSTRAK 
 
Imatinib mesylate (IM) adalah ubat perencat khusus untuk BCR-ABL tirosina 
kinase yang digunakan sebagai terapi utama pada pesakit leukemia mieloid kronik 
(CML). IM adalah sangat berkesan dan dianggap sebagai penjagaan piawai dalam 
pengurusan CML. Walaupun IM telah menjadi piawai utama dalam rawatan CML, 
rintangan kepada IM telah muncul sebagai masalah utama yang membimbangkan. 
Hampir 33% daripada pesakit CML yang menjalani terapi IM mengalami rintangan yang 
disebabkan oleh sama ada mekanisma bersandar BCR-ABL atau mekanisma tak 
bersandar BCR-ABL. Mekanisma bersandar BCR-ABL melibatkan mutasi titik dalam 
domain BCR-ABL tirosina kinase dan amplifikasi gen BCR-ABL. Mekanisma tak 
bersandar BCR-ABL terdiri daripada beberapa faktor termasuk perubahan dalam 
farmakokinetik IM yang bergantung kepada penyerapan, pengedaran metabolisma serta 
perubahan epigenetik. Kajian ini telah dijalankan untuk menjelaskan mekanisma yang 
bersandar kepada BCR-ABL dan mekanisma tak bersandar BCR-ABL yang melibatkan 
perubahan epigenetik, pada pesakit CML di Malaysia yang menjalani terapi IM. 
Sejumlah 205 pesakit CML yang menjalani terapi IM (122 rintang terhadap IM dan 83  
mempunyai respon yang baik terhadap IM) menyertai kajian ini. Menggunakan 
Penyahaslian Kromatografi Cecair Prestasi Tinggi (dHPLC) diikuti oleh penjujukan 
DNA, 122 pesakit CML yang rintang terhadap IM telah disaring untuk mutasi BCR-
ABL. Sembilan puluh dua pesakit CML yang rintang terhadap IM dan yang tidak 
menunjukkan mutasi BCR-ABL (BCR-ABL tidak termutasi) telah dikaji buat 
mengenalpasti kehadiran amplifikasi gen BCR-ABL. Sebagai sebahagian daripada 
pendekatan epigenetik, 175 pesakit CML yang terdiri daripada 83 pesakit respon baik 
xxii 
 
dan 92 pesakit rintang terhadap IM yang tidak termutasi di uji menggunakan Analisis 
Pencairan Resolusi Tinggi Spesifik kepada Metilasi (MS-HRM). Dalam analisis mutasi 
BCR-ABL, mutasi dikesan pada 30/122 pesakit (24.6%) dengan dua daripada pesakit 
CML menunjukkan mutasi berganda. Tujuh belas jenis mutasi (T315I, G250E, E255K, 
E255V, M351T, Y253H, V289F, E355G, F359V, L387M, H396R, E355A, D276G, 
A397P dan E281K) termasuk dua mutasi novel (G251E dan N368S) telah dikenal pasti. 
Oleh kerana mutasi yang berbeza memberikan tahap kerintangan yang berbeza, 
pengesanan dan pencirian mutasi BCR-ABL adalah sangat relevan pada pesakit CML 
untuk menjadi panduan dalam memilih dos IM yang paling sesuai atau menukar kepada 
terapi TKI lain. Walau bagaimanapun, 92 pesakit CML yang rintang terhadap IM yang 
mempunyai BCR-ABL tidak termutasi, tidak menunjukkan amplifikasi gen BCR-ABL. 
Berhubung dengan mekanisma tak bersandar BCR-ABL, tahap metilasi HOXA4 dan 
HOXA5, tetapi bukan SOCS1, didapati lebih tinggi pada pesakit CML yang 
menunjukkan kerintangan. Pesakit CML yang dirawat dengan IM yang mempunyai 
tahap metilasi HOXA4 dan HOXA5 lebih tinggi daripada 62.5% didapati berkait dengan 
dengan risiko yang lebih tinggi (OR, 4.71; 95% CI, 2.46, 9.03; P <0.001 dan OR, 4.26; 
95% CI, 2.22, 8.17; masing-masing P<0.001) untuk mengalami kerintangan terhadap IM 
berbanding dengan kumpulan yang bertidak balas secara optimum terhadap IM. 
Hipermetilasi pada pengalak gen HOXA4 dan HOXA5 boleh dianggap sebagai salah satu 
daripada mekanisma tak bersandar BCR-ABL yang  menyebabkan kerintangan terhadap 
IM dan berpotensi menjadi penanda bio epigenetik, sebagai tambahan kepada mutasi 
gen BCR-ABL dalam meramalkan tindak balas terhadap rawatan IM  di kalangan pesakit 
CML. Dalam lima tahun analisis kemandirian, kehadiran mutasi BCR-ABL terutama 
mutasi Y253H dan E355G (masing-masing P=0.005 dan P=0.025) didapati berkaitan 
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dengan prognosis dan kemandirian pesakit CML yang dirawat dengan IM. Walau 
bagaimanapun, selepas pelarasan bagi pembolehubah lain dalam analisis regresi Cox 
berganda, peringkat CML telah muncul sebagai satu-satunya faktor ramalan yang 
penting (HR: 27.04, P<0.001 untuk BP dan HR: 9.58, P<0.001 untuk AP). Keputusan 
keseluruhan menunjukkan bahawa kerintangan terhadap IM bukan disebabkan oleh 
mekanisma tunggal atau mudah, tetapi disebabkan fenomena multi-faktorial. Mutasi 
BCR-ABL boleh dianggap sebagai penanda molekul untuk meramalkan tindak balas 
serta prognosis pesakit CML dalam rawatan IM manakala tahap metilasi pada penggalak 
HOXA4 dan HOXA5 boleh dianggap sebagai penanda epigenetik untuk meramalkan 
tindak balas kepada IM. 
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ABSTRACT 
 
Imatinib mesylate (IM) is a BCR-ABL targeted tyrosine kinase inhibitor drug 
used for frontline therapy in patients with chronic myeloid leukemia (CML). IM is 
highly effective and is considered the standard of care in CML management. Even 
though IM has become the gold standard frontline treatment of CML, resistance to IM 
has emerged as a major problem of concern. Nearly 33% of CML patients on IM therapy 
develop resistance which can be either due to BCR-ABL dependent or BCR-ABL 
independent mechanisms. BCR-ABL dependent mechanism involves point mutation in 
the BCR-ABL tyrosine kinase domain and amplification of the BCR-ABL gene. BCR-
ABL independent mechanisms include several factors including alteration in 
pharmacokinetics of IM with respect to absorption, distribution of metabolism as well as 
epigenetic alterations. The present study was undertaken to elucidate the BCR-ABL 
dependent mechanism and BCR–ABL independent mechanism involving epigenetic 
alterations, in Malaysian CML patients undergoing IM therapy. A total of 205 CML 
patients on IM therapy (122 IM resistant and 83 IM good response) were included in this 
study. Using denaturing High Performance Liquid Chromatography (dHPLC) followed 
by DNA sequencing, 122 IM resistant CML patients were screened for BCR-ABL 
mutations. Ninety two IM resistant CML patients who did not show BCR-ABL mutations 
(BCR-ABL non-mutated) were investigated for BCR-ABL gene amplification. As part of 
epigenetic approach, 175 CML patients comprising of 83 good response and 92 IM 
resistant BCR-ABL non-mutated CML patients were subjected to Methylation Specific 
High Resolution Melt Analysis (MS-HRM). In BCR-ABL mutation analysis, mutations 
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were detected in 30/122 patients (24.6%) with two of the CML patients showing double 
mutations. Seventeen different types of mutations (T315I, G250E, E255K, E255V, 
M351T, Y253H, V289F, E355G, F359V, L387M, H396R, E355A, D276G, A397P and 
E281K) including two novel mutations (G251E and N368S) were identified. Since 
different mutations confer different levels of resistance, detection as well as 
characterization of BCR-ABL mutations is highly relevant in CML patients to guide in 
selecting the most suitable IM dosage or changing to other Tyrosine kinase inhibitor 
therapy.  However, the 92 IM resistant BCR-ABL non-mutated CML patients did not 
show amplification of the BCR-ABL gene. With regard to BCR-ABL independent 
mechanism, methylation levels of HOXA4 and HOXA5, but not of SOCS1, were found to 
be higher in CML patients showing resistance. IM treated CML patients with higher 
than 62.5% of HOXA4 and HOXA5 promoter methylation levels were found to be 
associated with a higher risk (OR, 4.71; 95% CI, 2.46, 9.03; P<0.001 and OR, 4.26; 95% 
CI, 2.22, 8.17; P<0.001, respectively) for developing IM resistance compared to the 
optimal response group. Promoter hypermethylation of HOXA4 and HOXA5 genes could 
be considered as one of the BCR-ABL independent mechanisms mediating IM resistance 
and could be a potential epigenetic biomarker in supplement to the BCR-ABL gene 
mutation in predicting IM treatment response among CML patients. In a five-year 
survival analysis, the presence of BCR-ABL mutations especially Y253H and E355G 
mutations (p-value =0.005 and p-value =0.025 respectively), were found to be associated 
with the prognosis and survival of CML patients on IM therapy. However, after 
adjusting for other variables in multiple Cox regression analysis, CML stage has 
emerged as the only significant prognostic factor (HR: 27.04, p-value <0.001 for BP and 
HR: 9.58, p-value <0.001 for AP). The overall results suggest that resistance to IM is not 
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due to a single or simple mechanism, but is a multi-factorial phenomenon. BCR-ABL 
mutations could be considered as molecular marker for predicting the IM response as 
well as prognosis of CML patients on IM treatment whereas promoter methylation levels 
of HOXA4 and HOXA5 could be considered as epigenetic markers for predicting the 
response to IM.  
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CHAPTER 1 
 
INTRODUCTION 
 
1.1   Cancer – An Overview 
Worldwide, cancer is responsible for several million annual deaths. In 2008, 
cancer accounted for 7.6 million deaths, which was around 13% of all deaths (WHO, 
2008). Cancer was reported to be the third common cause of death in hospitals under the 
Ministry of Health, Malaysia in 2007 (11.28%), after heart diseases and diseases of 
pulmonary circulation and septicaemia. According to the Malaysian National Cancer 
Registry report, a total of 18,219 new cancer cases were registered with the National 
Cancer Registry in 2007, which comprised of 8,123 (44.6%) males and 10,096 (55.4%) 
females (Omar and Tamin, 2011).  
However, the trend of cancer incidence rate in Malaysia was reported to be 
decreasing. The age-standardised incidence rates (ASR)  for all cancers in the year 2003 
was 134.3 per 100,000 males and 154.2 per 100,000 females (Lim and Halimah, 2003). 
In the following three years, the ASR among males was 128.6 per 100,000 population 
and among females was 135.7 per 100,000 population (Omar et al., 2006). The trend 
was further decreased in 2007 when the ASR were reported as 85.1 per 100.000 in males 
and 94.4 per 100,000 in females (Omar and Tamin, 2011). In all of these three studies, 
age-standardized incidence was identified rather than the incidence rate as age-
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standardized incidence is more reliable. This is because, age-standardized incidence was 
calculated with the reference population being the World Standard Population. 
Cancer is not one single disease, but a complex group of around 200 diseases, in 
which there is a diminution in control over cell proliferation and cell death in the 
affected tissues. Cancer, also known as malignant neoplasm, originates from a single 
abnormal cell which grows and divides without obeying normal cell cycle regulatory 
mechanisms and acquires the ability to invade local tissue and spread distantly to other 
parts of the body (metastasize). 
There are eight hallmarks of cancer which are 1) sustaining proliferative 
signalling, 2) evading growth suppressors, 3) resisting cell death, 4) enabling replicative 
immortality, 5) inducing angiogenesis, 6) activating invasion and metastasis, 7) 
reprogramming of energy metabolism and 8) evading immune destruction (Hanahan and 
Weinberg, 2011). These changes in cellular behaviour are the result of alterations in the 
function or levels of the proteins that control these processes. And these alterations are, 
in turn, usually caused by mutations, or changes in expression of genes encoding the 
proteins. 
 
1.1.1    Cancer Development 
Development of cancer is a complex, multistep process and involves several 
mechanisms. Basically, cancer arises from the accumulation of multiple genetic 
alterations in responsible genes that are involved in many molecular pathways. There are 
two major classes of genes, oncogenes and tumour suppressor genes (TSGs), that are 
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responsible for cancer formation. The products of all these genes are all part of a 
network that work collectively in controlling cell proliferation, differentiation and 
survival (Boyle et al., 2008).  
In general, oncogenes (called proto-oncogenes in their normal, non-mutated 
form) promote cell proliferation and survival, whereas tumour suppressor genes inhibit 
cell growth. Cells proliferate only when required, as a result of delicate balance between 
growth promoting and growth inhibiting mechanisms that are controlled by an intricate 
network of intra- and extra cellular molecules. But cancer cells, in stark contrast, 
override these controlling mechanisms and follow their own internal program for timing 
their reproduction.  
Another group of genes that are responsible in cancer formation is the DNA 
repair genes. There are increasing evidence and reports which demonstrate that 
breakdown of DNA repair genes can cause development of human cancers (Mendelsohn 
et al., 2008).  
 
1.1.2   General Classification of Cancer 
Generally, cancers are classified in two ways, which are based on the histological 
type of tissue in which the cancer originates (histological type) or the location in the 
body where the cancer first develops (primary site). Based on the histological 
perspective, there are hundreds of different cancers. However, according to U.S. 
National Institutes of Health, cancer can be grouped into six major categories, which are 
the carcinoma, sarcoma, myeloma, leukemia, lymphoma and mixed type. 
4 
 
Carcinoma is a type of cancer that originates at the internal or external epithelial 
lining of the body. Malignancies of epithelial tissue account for 80 to 90 percent of all 
cancer cases. Carcinomas are divided into two major subtypes which are 
adenocarcinoma and squamous cell carcinoma. The major difference between them is, 
adenocarcinoma develops in an organ or gland but squamous cell carcinoma originates 
in the squamous epithelium. 
Sarcoma is a type of cancer that originates in supportive and connective tissues 
such as bones, tendons, cartilage, muscle, and fat. Examples for sarcomas are 
Osteosarcoma which occurs in bone, Chondrosarcoma that occurs in cartilage and 
Liposarcoma that develops in adipose tissue. 
 Myeloma is a type of cancer that originates in the plasma cells of bone marrow. 
The plasma cells produce some of the proteins found in blood. Thus, myeloma can lead 
to excess of protein in blood plasma. Because plasma cells are part of the immune 
system and produce antibodies, the development of myeloma results in antibody 
overproduction, thus impairing the immune system. 
 The leukaemias are neoplastic proliferations of cells of the haematopoietic (blood 
forming) lineage. Leukemia, also known as “blood cancer”, develops in the bone 
marrow or blood often leading to the overproduction of immature white blood cells 
which can travel to any part of the body. These immature white blood cells do not 
perform what they are supposed to do normally. Consequently, the patient is often prone 
to infection. Leukemia also can affect red blood cells and can cause series of bleeding 
due to poor blood clotting and fatigue due to anemia. 
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 Lymphoma is a solid cancer that develops in the glands or nodes of the lymphatic 
system, a network of vessels, nodes, and associated organs (specifically the spleen, 
tonsils, and thymus) that purify bodily fluids and produce infection-fighting white blood 
cells (lymphocytes). 
 Cancer also can present in mixed type, in which the type components may be 
within one category or from different categories. A few examples of mixed type of 
cancer are adenosquamous carcinoma (contains two types of cells: squamous cells and 
gland-like cells) and carcinosarcoma (malignant tumor that is a mixture of carcinoma 
and sarcoma). 
According to the U.S. National Institutes of Health, the international standard for 
the classification and nomenclature of histology is the International Classification of 
Diseases for Oncology, Third Edition (ICD-O-3) (WHO, 2000). 
    
1.2   Overview of Leukemia 
Leukemia is usually defined as the uncontrolled proliferation or expansion of 
haematopoietic cells that do not retain the capacity to differentiate normally to mature 
white blood cells. As white blood cells are part of body’s immune system, the disorder 
in the white blood cells production will impair body’s defence against infection (Panno, 
2010). In 2010, the incidence of leukemia was reported to be increasing over the years, 
from 30,800 cases in year 2000 to 44,790 in the year 2009 worldwide (Panno, 2010). In 
another report, it was estimated that by 2012, 47,150 people would be diagnosed with 
and 23,540 people would die of leukemia in United States (Howlader et al., 2012). 
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In Malaysia, leukemia was reported to be the seventh most frequent cancer in 
2007 (Table 1.1), after lymphoma and cancer of the uterine cervix, and it accounted for 
4.1% of all types of cancer (Omar and Tamin, 2011). In 2003, the age-standardised 
incidence rates (ASR)  for leukemia was reported to be 7.2 per 100,000 males and 5.3 
per 100,000 females (Lim and Halimah, 2003). In the following three years, the ASR 
among leukemia patients decreased on a large scale wherein the ASR for male leukemia 
patients was 4 per 100,000 population and for female leukemia patients was 2.4 per 
100,000 population (Omar et al., 2006). However, the trend fluctuated in 2007, when the 
ASR was reported as 3.5 per 100.000 in males and 2.7 per 100,000 in females (Omar 
and Tamin, 2011). Due to the inconsistent ASR trend of CML patients, it is crucial to 
study on the factors that may involve and on how to overcome fluctuation in the ASR of 
Malaysian CML patients.  
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Table 1.1: Ten most frequent cancers in Malaysia (2007), with leukemia as the seventh 
most frequent cancer (adapted from Omar & Tamin, 2011). 
Type of Cancer No. Of patients Percentage (%) 
Breast 3292 18.1 
Colorectal 2246 12.3 
Trachea, Bronchus, Lung 1865 10.2 
Nasopharynx 940 5.2 
Cervix Uteri 847 4.6 
Lymphoma 776 4.3 
Leukaemia 741 4.1 
Ovary 656 3.6 
Stomach 630 3.5 
Liver 605 3.3 
 
 
1.2.1   Types of Leukemia 
Usually, leukemia is divided into two main classes; acute and chronic leukemia. 
The terms acute and chronic refer to the rate at which the disease progresses, in which 
acute refers to rapid progression and chronic refers to slow progression (Bozzone, 2009). 
Acute leukemia shows a fast clinical pattern and can result in death in a relatively short 
period of time whereas chronic leukemia is generally less aggressive and patients might 
live with this disease for several years if treated. Both acute and chronic leukemia are 
subdivided into different categories based on the lineage and cell type involved. 
Leukemia that arises from lymphoid cells is categorized into lymphocytic leukemia and 
leukemia that arises from myeloid cells is categorized into myelogenous leukemia 
(Panno, 2010). 
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There are four main types of leukemia which are the acute lymphocytic leukemia 
(ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) and 
chronic myeloid leukemia (CML).  
Acute lymphoblastic leukemia (ALL) is a type of leukemia, marked by neoplasia 
of precursor B- or precursor T-lymphoid cells in blood. ALL  is reported to be the most 
common cancer among children (Gurbuxani and Anastasi, 2011) and it accounts for 75 
percent of childhood leukemia with highest incidence among children aged 1 to 10 
years. In ALL, accumulation of leukemic lymphoblasts in the bone marrow and 
extramedullary site such as thymus occur due to abnormal proliferation, differentiation 
arrest as well as apoptosis resistance of the leukemic cells (Gurbuxani and Anastasi, 
2011). Thus, normal hematopoiesis will progressively decline and may lead to anemia, 
infection, bleeding, splenomegaly, hepatomegaly, lymphadenophaty and other 
manifestation of organ infiltration (Gurbuxani and Anastasi, 2011). However, ALL 
presentation is usually acute with non-specific signs and symptoms.  
Chronic lymphoid leukemia (CLL) is a type of leukemia that affects lymphoid 
cells (lymphoproliferative disorder of the B lymphocytes) and usually this disease grows 
slowly. It mostly affects people more than 55 years old and most likely never affects 
children (Panno, 2010). In western countries, CLL is reported to be the most common 
form of leukemia in adults and more than 10,000 people are diagnosed each year in the 
United States alone and the survival rate is approximately 75% (Bozzone, 2009).  
AML is a type of leukemia that affects the myeloid cells. However, unlike CML, 
AML usually grows rapidly and affects both children and adults. Clinically, AML is 
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characterized by accumulation of immature blastic cells that proliferate abundantly with 
lack of normal differentiation (Mendelsohn et al., 2008). AML involves various 
morphologic, immunologic and genetic subtypes that are associated to a very diverse 
clinical profiles and treatment results, leading to an increasing role of the prognostic 
parameters (Kern et al., 2011). 
The fourth type of leukemia is chronic myeloid leukemia (CML) of which the 
present study is being focused on. 
 
 
1.3   Chronic Myeloid Leukemia – Molecular Pathogenesis 
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disease, 
originating from an abnormal pluripotent bone marrow stem cell. The progression of 
CML is slow during the early stage. CML is very rarely found in children and its 
incidence increases in older ages. Making it more complex, there are no known 
hereditary, familial, geographic, ethnic, or economic factors that can be associated with 
CML. Therefore, the disease is neither preventable nor inherited (Quintas-Cardama and 
Cortes, 2006) and the cause for its formation is unknown in the majority of patients 
(Yong and Melo, 2011). 
Historically, CML is the first type of leukemia to be recognized (Goldman, 2010) 
and is the first human cancer to be associated with a consistent chromosomal 
abnormality (Yong and Melo, 2011). The hallmark of CML identification is the presence 
of a minute chromosome known as Philadelphia chromosome in the bone marrow cells. 
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The Philadelphia chromosome was first discovered by Nowell and Hungerford in 1960. 
With improvements in techniques, the formation of Ph chromosome was characterized 
as to be the result of reciprocal translocation between chromosome 9 and 22, 
t(9;22)(q34;q11) by Rowley (1973). (Rowley, 1973) (Nowell and Hungerford, 1960) 
In early 1980s, the enhancement of molecular biology led to the discovery of 
human homologue of the murine Abelson1 gene (ABL1 gene) which is normally located 
on human chromosome 9 but was then found to be translocated to the chromosome 22 
(Ph chromosome) in most of the CML patients (Goldman, 2010). Later, in 1984, 
description of the breakpoint cluster region (BCR gene) on chromosome 22 was 
explored and consequently, a theory of possibility that the BCR and ABL1 might be 
linked in some way that led to activation of ABL1 was raised (Goldman, 2010).  
 The Philadelphia chromosome translocation results in a BCR-ABL fusion gene 
that codes for fusion proteins with unusual tyrosine kinase activity. The fused BCR-ABL 
proteins are capable of interacting with the interleukin-3 beta receptor and activating a 
cascade of proteins which speed up cell division. Also, BCR-ABL tyrosine kinase 
activity does not require activation by cell signalling molecules; it is constitutively 
active unlike normal kinases. Hence white blood cells containing the fusion protein are 
able to proliferate without the presence of growth factors. In addition, BCR-ABL fusion 
proteins inhibit the DNA repair, leaving the cell more susceptible to genetic 
abnormalities. Cumulative effect of these molecular mechanisms makes CML a 
progressive disease that develops in three stages. 
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1.3.1   Incidence of Chronic Myeloid Leukemia 
CML is not a common disease worldwide (Quintas-Cardama and Cortes, 2006; 
Rodgers and Young, 2010). Its annual incidence is 1–2 per 100,000 people, and slightly 
more men than women are affected (1.5:1) (Rodgers and Young, 2010). CML generally 
occurs in adults and occurs less than three percent in individuals aged from infancy to 19 
years old. Thus CML is very rare in children, with less than 50 cases per year diagnosed 
in the United States (Bozzone, 2009).  
In the Surveillance Epidemiology and End Results (SEER) report from United 
Kingdom, the age-adjusted incidence rate of CML for the period 2005 to 2009 was 
reported as 1.6 per 100,000 men and women per year (Howlader et al., 2012). It was 
reported that the incidence rate of CML in Asian Pacific countries are lower than the 
western countries. The annual incidence of CML per 100,000 populations in Asia pacific 
region, was reported to be ranging from 0.4 in China up to 1.0 in Japan (Kim et al., 
2010a).  
It was reported that CML represents about 15–20% of all cases of adult leukemia 
in Western populations. In Malaysia, occurrence of CML in 2007 was reported as 14.1% 
of all types of leukemia and 21.9% of myeloid group of leukemia (Omar and Tamin, 
2011).  
Even though incidence rate in Asia is lower than in Western countries, it is 
devastating that the occurrence of CML in Asia pacific countries tends to afflict younger 
population with median age as low as 36 years (Au et al., 2009). In United State 
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population, the median age of CML diagnosis was reported as approximately 50 years 
(Bozzone, 2009).  
 
1.3.2   Clinical Features of Chronic Myeloid Leukemia 
Almost 20% of CML patients are asymptomatic (Alagappan, 2011). However, 
classical presentation of CML includes fever, rapid weight loss, lassitude, night sweats, 
gout and splenic pain, which refer to substantial splenomegaly (Alagappan, 2011). 
Leucostasis with leucocyte counts greater than 300,000/ uL accompanied with headache 
and focal neurologic deficits may also be present (Rodgers and Young, 2010). However, 
explicit signs and symptoms are rarely encountered among the CML patients nowadays, 
as the diagnosis is usually made earlier. Consequent to early diagnosis, commonly, 
patients only present with fatigue, with or without weight loss, abdominal discomfort or 
simply an observation of elevated leukocyte count in routine blood test (Rodgers and 
Young, 2010). 
  Even though many CML patients are diagnosed in an early stage, rare 
presentations of CML may also be observed among the patients including chloroma, 
petechiae and bruising, suggesting the progression of CML to an accelerated or blast 
phase. Ironically, unlike other types of leukemia, CML seldom presents with bacterial or 
fungal infection due to the preservation of neutrophil functions (Rodgers and Young, 
2010).  
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1.3.3   Diagnosis of Chronic Myeloid Leukemia 
In western countries, most patients tend to be diagnosed in the chronic phase 
where diagnosis is often made on the basis of routine blood testing in which 85% of 
patients are diagnosed in the chronic phase and half are asymptomatic at their early 
period of presentation (Laneuville et al., 2006). In Asian Pacific countries, 
approximately 84% of cases are diagnosed in chronic phase (CP). Minorities of the 
CML patients are diagnosed in accelerated phase (AP) (~11%) or blast crisis (BC) 
(~5%) (Kim et al., 2010a). However, in Malaysia, the percentage of CML patients 
diagnosed in AP and BC has been reported as quite high compared to other countries, 
with approximately 30% and 10% of CML patients being diagnosed in AP and BC, 
respectively (Kim et al., 2010a).  
The diagnosis of CML is usually based on blood count, blood film, bone marrow 
aspirate, cytogenetic analysis and molecular diagnosis. Complete blood count is usually 
applied as the first indicator of CML diagnosis. Usually, leukocyte number in CML 
patient varies from 200,000 to 700,000 per cubic millimetre with normal or elevated 
platelet counts. Mild normochromic normocytic anemia may also be present (Rodgers 
and Young, 2010; Alagappan, 2011). 
Consequent to abnormal blood count, blood film screening is done. CML has a 
unique blood film, with left shift circulating myeloblasts, myelocytes, metamyelocytes 
and band forms (Figure 1.1). Uniquely in CML cases, basophil counts usually exceed 
1000 per cubic millimetre and is a hallmark in CML diagnosis (Rodgers and Young, 
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2010). Abnormal result in blood film screening is usually followed with bone marrow 
aspirate analysis which is a more invasive procedure.  
 
 
Figure 1.1: Blood smear of CML showing neutrophilic leukocytosis with left shift and 
basophilia (adapted from Krafts, 2009). (Krafts, 2009)  
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CML bone marrow aspirate usually shows cellular spicules, hypercellularity, and 
almost complete effacement of the fat spaces. The cell morphology shows granulocytic 
hyperplasia of neutrophil, eosinophil and basophil series as a feature of myeloid 
predominance in marrow (Naeim, 2001; Rodgers and Young, 2010). Megakaryocytes 
are abundant in CML marrow and show marked variety of morphology ranging from 
small size to large, bizarre, multilobulated forms (Naeim, 2001). Progression of CML to 
accelerated phase is featured by an increase of blast cells up to 15% and blastic phase is 
featured by an increase of blast cells more than 20%. 
 
1.3.4   Haematological and Bone Marrow Abnormalities in Chronic Myeloid 
Leukemia 
 Patients with CML are usually presented with several haematological 
abnormalities. The typical haematologic findings are anaemia with haemoglobin level 
less than 7 gm/dl to 11 gm/dl as well as marked leukocytosis with elevation of total 
leukocyte count from 100 to 500 X10
9 
/L (Singh, 2008). In peripheral blood smear, 
CML patients demonstrate immature white cells of all stages including neutrophils, 
metamyelocytes, myelocytes, promyelocytes and blast cells. Basophils and eosinophils 
may also increase up to 5% to 15%.  
 Apart from those haematologic findings, CML patients also show a decline in 
neutrophil alkaline phosphatase score to as low as 0 to 20. However, platelet count is 
higher in CML patients (thrombocytosis), at the range of 300 to 500 X 10
9 
/L (Singh, 
2008). 
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 Bone marrow smear of CML patients are usually presented with marked myeloid 
hyperplasia together with a markedly increase of myeloid to erythroid precursor (M:E) 
ratio from 20:1 to 49:1 (Singh, 2008). Thus, erythriod cells gradually diminish, resulting 
in anaemia consequential to myeloid hyperplasia. CML patients in chronic phase are 
usually presented with 2% to 5% blast cells. 
Further, cytogenetic analysis for CML diagnosis is also crucial for absolute 
confirmation of the disease. More than 95% patients that present with clinical and 
morphologic features of CML have Philadelphia (Ph) chromosome in the marrow with 
typical karyotype of the reciprocal translocation t(9;22) (q34;q11). Variant Ph 
translocation also may be present in 5% of CML patients. Variant Ph translocation 
include three-way translocations involving chromosomes 9, 22 and any one of the 22 
pairs of autosomes (Rodgers and Young, 2010). 
More recently, molecular diagnostic methods including fluorescence in situ 
hybridization (FISH) and quantitative reverse transcription polymerase chain reaction 
(qRT-PCR) have been introduced and were reported to be more sensitive than 
conventional cytogenetic analysis for the detection of BCR-ABL1 positive cells. In the 
qRT-PCR, the BCR-ABL transcript in the peripheral blood sample is measured in 
relation to the housekeeping gene glucose-6-phosphate dehydrogenase (G6PDH) 
(Gadzicki et al., 2005). Molecular diagnosis of CML is based on the detection of BCR-
ABL gene fusion transcripts using the qRT-PCR (Goh et al., 2006). 
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1.3.5   Stages of Chronic Myeloid Leukemia 
CML is a triphasic disease that progress from a chronic phase (CP) to accelerated 
phase (AP) and finally worsens to Blast Phase (BP). Chronic phase can be distinguished 
from the other advanced phases by looking at several factors. Patients at CP have less 
than 15% of blasts in blood and less than 20% in bone marrow (Rodgers and Young, 
2010). In CP, Ph chromosome can also be detected through cytogenetic analysis. 
Duration of CP in CML patients is highly variable before progression to more advance 
phases. CP can last as short as from months to as long as years with commonly from 
three to five years (Bozzone, 2009). However, median time to progression from CP to 
AP is slowly increasing due to better treatment and earlier diagnosis of CML patients.  
AP takes place after the progression from the CP. AP is defined as having one or 
more of the following criteria; increase in number of blasts in peripheral blood (15% to 
30%) and in bone marrow (20% to 50%) , Leukocytosis (>50 x10
9
 leukocytes per liter), 
anemia (hematocrit, <25%), thrombocytopenia (<100 x10
9
 thrombocytes per liter) that is 
not controlled with antileukemic therapy, marked thrombocytosis (>1000 x10
9
 
thrombocytes per liter) or myelofibrosis with teardrop cells in blood smear and increased 
marrow reticulin (Faderl et al., 1999; Rodgers and Young, 2010).  
During AP, more genetic errors are accumulated in cells and the production of 
abnormal cells are markedly increased. Distraughtly, AP can only last from three to nine 
months before it progresses into even worse stage if the CML patients are not treated 
well enough (Bozzone, 2009). 
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The third and last stage of CML is the blastic phase. The signs and symptoms of 
BP resemble acute leukemia, which consist of bone pain, weight loss and B symptoms 
(systemic symptoms of fever, night sweats, and unintentional weight loss of >10% of 
normal body weight over a period of six months or less). Blasts cells are usually 
increased to more than 30% in peripheral blood and more than 50% in bone marrow. 
Marrow failure can also be observed, marked by decreasing red blood cell and platelets 
count. Cytogenetically, further additional chromosomal abnormalities are also frequently 
observed in BP CML patients. Usually, CP can last from three to six months (Bozzone, 
2009). 
 During BP, even more genetic errors are accumulated in the leukemic cells, 
especially in tumor suppressor genes. Thus, the cells tend to proliferate very swiftly and 
are unresponsive to signals that initiate apoptosis and die (Bozzone, 2009). 
Consequently, if patients in BP are left untreated, the blast crisis can be life threatening. 
 
1.4    Treatment of Chronic Myeloid Leukemia 
Treatment of CML was previously focused on normalizing the number of 
peripheral blood granulocytes. Before 2001, hydroxyurea was used and was considered 
as the standard treatment for newly diagnosed CML patients (Tahir et al., 2007). 
Hydroxyurea works by inhibiting one of the enzymes involved in DNA replication, and 
thus suppressing the excessive multiplication of the myeloid peripheral cells. 
Hydroxyurea was reported to help relieve symptoms with few adverse effects and 
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produce haematological remission in over 90% of CML patients without affecting the 
expression of the Ph chromosome phenotype (Au et al., 2009). 
After the introduction of Interferon- α (IFN- α), this treatment was used widely 
and was sometimes combined with hydroxyurea when the treatment with IFN- α failed, 
or when IFN- α was not tolerated, or in very elderly or frail people (Tahir et al., 2007).  
However, only small group of the IFN-α treated CML patients reach complete 
cytogenetic remission (CCyR). IFN-α acts by down-regulating BCR-ABL1 gene 
expression, activating several transcriptional factors that control cell proliferation, 
maturation, and apoptosis as well as promoting the cycling of normal dormant 
hematopoietic stem cells thereby exposing leukemic stem cell to the action of 
chemotherapy agents (Kreutzman et al., 2011). 
The discovery of BCR-ABL mediated pathogenesis of CML has provided the 
rationale for designing a drug that targets the kinase activity of BCR-ABL fusion protein. 
Imatinib mesylate (also known as Glivec/Gleevec) is the molecularly targeted drug that 
acts on the molecular mechanisms that leads to CML- the unusual tyrosine kinase 
protein coded for by BCR-ABL1 fusion gene. 
In 2001, imatinib mesylate (IM), the first tyrosine kinase inhibitor (TKI), was 
approved by the United States Food and Drug Administration for the treatment of CML 
(Cohen et al., 2002). A high percentage (81%) of CML patients who received IM as the 
frontline treatment was reported to achieve complete cytogenetic response (Roy et al., 
2006). Since then, IM has been widely used as the frontline treatment for CML patients. 
Thus, IM is now accepted worldwide in the treatment and management of CML patients. 
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The efficiency of CML treatment is usually monitored and measured based on 
the remission status of the disease condition which is evaluated on three main criteria. 
The earliest monitoring of IM response is on the haematologic remission of the CML 
patients. The monitoring should be done every 15 days until complete haematologic 
response is achieved or at least every three months after the initiation of IM therapy. 
Later, at three months, six months and 12 months, Cytogenetic analysis is carried out for 
cytogenetic response monitoring of the CML patients, aiming for complete cytogenetic 
response. After every six months, or at least after 18 months of IM initiation, molecular 
monitoring is carried out, aiming for undetectable BCR-ABL1 mRNA transcripts by real 
time quantitative PCR and this is termed as complete molecular response. More details 
of treatment response monitoring is described in Chapter Two. 
  
 
1.5    The Present Study: Rationale and Importance 
Even though IM has become the gold standard frontline treatment of CML, 
resistance to this drug has emerged as an increasing problem of concern. Development 
of resistance to IM has been a setback for patients and physicians facing this clinical 
crisis and remains a daunting situation. Resistance to IM is a major problem because it 
can develop at any time and lead to disease progression. In an International Randomized 
Study of Interferon and SST1571 (IRIS) study, it was reported that, 15% of CML 
patients never even achieved partial cytogenetic response (PCyR) and loss of response 
was observed in 11% of patients with IM treatment (Roy et al., 2006). 
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Nearly one third of CML patients undergoing IM therapy, have an inferior 
response to IM, either failing to respond to primary therapy or demonstrating 
progression after an initial response. A patient with CML could display either a primary 
or secondary resistance to IM therapy. Primary resistance, which is also referred as 
refractoriness or failure, is defined as inability to achieve any landmark response from 
the very beginning of the treatment (Quintas-Cardama et al., 2009; Goldman, 2010). 
These patients may never achieve complete haematology response even after three 
months of IM treatment and/or complete cytogenetic response even after 12 months of 
IM treatment (Baccarani et al., 2009a; Baccarani et al., 2009b; LeukemiaNet, 2010).  
The second group is secondary resistance which is also known as acquired 
resistance. Patients categorized in secondary resistance group achieve complete 
cytogenetic response to IM for a period of time but the length of response varies 
between CML patients. Patients are classified into secondary resistance once an event of 
losing a major cytogenetic response and complete cytogenetic response occurred 
(Baccarani et al., 2009a; Baccarani et al., 2009b; Quintas-Cardama et al., 2009; 
LeukemiaNet, 2010). 
Therefore, in clinical practice, haematologic, cytogenetic and molecular response 
to IM is evaluated at regular periodic intervals to monitor the treatment response and 
development of either primary or secondary resistance (LeukemiaNet, 2010). In 
Malaysia, at HUSM and other collaborating centres, there are several CML patients 
undergoing IM treatment and who show signs of resistance to IM. This trend of CML 
progression due to the development of resistance towards IM treatment has become an 
alarming problem in the management of CML patients. 
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Development of resistance to IM is a multifactorial phenomenon in patients with 
CML and may be mediated by a diversity of mechanisms. However, there are two broad 
mechanisms of resistance; BCR-ABL dependent and BCR-ABL independent pathways 
(Hochhaus, 2006; Mauro, 2006). So, in these CML patients molecular, molecular 
cytogenetic and epigenetic studies could be helpful in elucidating the mechanisms of 
resistance involving both BCR-ABL dependent as well as BCR-ABL independent 
pathways. This is because, knowing the pattern of BCR-ABL1 dependent as well as other 
possible mechanisms among Malaysian IM resistant CML patients can be very helpful 
towards designing a better approach in patients’ treatment and management. 
BCR-ABL dependent pathways mainly consist of BCR-ABL1 kinase domain 
mutations and BCR-ABL1 gene amplification. Both of these parameters were reported to 
be associated with clinical resistance to IM therapy (Gorre et al., 2001; Virgili and 
Nacheva, 2010). Researchers have identified nearly 100 different types of BCR-ABL1 
mutations in different population groups worldwide (Hughes et al., 2009). The 
identification of the type of BCR-ABL1 mutation is very crucial as different type of 
mutations is known to be associated with different level of clinical resistance to IM 
(Bengio et al., 2011; Soverini et al., 2011).  
The duplication of the Ph chromosome resulting in two copies of the BCR-ABL1 
fusion gene was reported to be a common abnormality acquired during CML disease 
progression (Virgili and Nacheva, 2010). There have not been many reports on the 
prevalence of BCR-ABL1 gene amplifications among CML patients showing resistance 
to IM. However, few case studies have reported the association of BCR-ABL1 gene 
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amplification in CML patient(s) with resistance to IM treatment (Campbell et al., 2002; 
Gadzicki et al., 2005; Phan et al., 2008).  
Although there are reports on the occurrence of BCR-ABL mutations and BCR-
ABL1 gene amplifications, still, no reports are available from Malaysia as no previous 
studies have been undertaken till date. So, in the present study, it was aimed to elucidate 
the contribution of mutations in the tyrosine kinase domain and also amplification of the 
BCR-ABL1 gene, as BCR-ABL1 dependent mechanisms mediating resistance to IM in 
Malaysian CML patients. 
However, several CML patients showing IM resistance might not fit into the 
BCR-ABL dependent mechanisms as not all IM resistant CML patients might be having 
BCR-ABL1 mutation or BCR-ABL1 amplification. It was presumed that the mechanisms 
of IM resistance in such patients might be mediated through BCR-ABL independent 
pathways. As the progression and the development of resistance to IM treatment among 
CML patients involve a complex and multi factorial mechanism, a combination of BCR-
ABL dependent and BCR-ABL independent mechanisms is implicated. 
 BCR-ABL independent pathways of IM resistance may include several 
mechanisms such as pharmacokinetic variability in IM efflux, IM import, IM 
metabolism, IM binding or IM concentration, as well as activation of alternative 
signalling pathways and epigenetic modification (Bixby and Talpaz, 2009). Existing 
knowledge of genetic alterations is inadequate in addressing the issues of BCR-ABL 
independent mediated resistance to IM. Thus, it is very important and prolific to explore 
novel pathways that contribute to the development of resistance to IM. 
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It is well known that genetic alterations in the human genome are not the only 
cause in promoting cancer or resistance to cancer treatment. To date, association 
between epigenetic alterations of the epigenome with cancer development and cancer 
therapy response also have attracted the interest of many scientists around the world.  
The epigenome which is composed of chromatin, its modifications and DNA 
methylation, plays a critical role in controlling gene expression, as well as in drug 
responsiveness (Strathdee et al., 2004; Glasspool et al., 2006). Epigenetic silencing is a 
phenomenon whereby gene transcription may be suppressed through DNA methylation, 
resulting in decreased or no protein expression. Abnormal DNA methylation plays a role 
in inactivation of tumor transcript genes by means of promoter hypermethylation.  DNA 
hypermethylation can provide valuable markers for malignant progression, residual 
disease and response to treatment.   
Few studies (Esteller, 2003; Herman and Baylin, 2003) have suggested that DNA 
hypermethylation might play a role in disease progression in CML. In CML, increased 
epigenetic silencing of potential tumour suppressor genes has been reported (Esteller, 
2003) to correlate with disease progression in a certain proportion of patients treated 
with IM. Thus, it was hypothesized that there might be a relationship between epigenetic 
silencing and development of IM resistance in CML patients.  
Methylation of two types of HOXA genes, HOXA4 and HOXA5,  have  been 
reported to be strongly associated with  progression to blast crisis and poor response to 
IM in CML patients (Strathdee et al., 2007a). Since HOXA4 and HOXA5 
hypermethylation exhibits frequent correlation with disease progression and poor 
